Drotrecogin alfa (activated): Real-life use and outcomes for the UK

Critical Care

Volumn 12, Issue 2, 2008, Pages

  Rowan, Kathryn M ^a   Welch, Catherine A ^a   North, Emma ^a   Harrison, David A ^a  

^a and London School of Hygiene Tropical Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ABDOMINAL BLEEDING; ABDOMINAL INFECTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTENSIVE CARE; IRELAND; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SKIN BLEEDING; SOFT TISSUE DISEASE; THORAX DISEASE; THROMBOSIS; UNITED KINGDOM; UROGENITAL TRACT DISEASE; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; OUTCOME ASSESSMENT; REGRESSION ANALYSIS;

ANTI-INFECTIVE AGENTS; GREAT BRITAIN; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; OUTCOME ASSESSMENT (HEALTH CARE); PROTEIN C; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; SEPSIS;

EID: 44249085375     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6879     Document Type: Article

References (24)

1. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/ NEJM200103083441001 11236773
2. FDA Anti-Infective Drugs Advisory Committee Summary Minutes of the October 16, 2001 Meeting Discussing Biologic License Application (BLA) 125029 Xigris™ (drotrecogin alfa [activated]) Eli Lilly and Company, Indianapolis, Indiana, USA 2001.
3. Warren HS Suffredini AF Eichacker PQ Munford RS Risks and benefits of activated protein C treatment for severe sepsis N Engl J Med 2002, 347:1027-1030. 10.1056/NEJMsb020574 12324562
4. Siegel JP Assessing the use of activated protein C in the treatment of severe sepsis N Engl J Med 2002, 347:1030-1034. 10.1056/NEJMsb021512 12324563
5. Ely EW Bernard GR Vincent JL Activated protein C for severe sepsis N Engl J Med 2002, 347:1035-1036. 10.1056/NEJM200209263471315 12324564
6. Eichacker PQ Natanson C Danner RL Surviving sepsis: Practice guidelines, marketing campaigns, and Eli Lilly N Engl J Med 2006, 355:1640-1642. 10.1056/NEJMp068197 17050887
7. Harrison DA Welch CA Eddleston JM The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: Secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database Crit Care 2006, 10:R42. 1550902 16542492 10.1186/cc4854
8. Harrison DA Brady AR Rowan K Case mix, outcome and length of stay for admissions to adult, general critical care units in England, Wales and Northern Ireland: The Intensive Care National Audit & Research Centre Case Mix Programme Database Crit Care 2004, 8:R99-111. 420043 15025784 10.1186/cc2834
9. DoCDat - The Directory of Clinical Databases http://www.docdat.org
10. Harrison DA Parry GJ Carpenter JR Short A Rowan K A new risk prediction model for critical care: The Intensive Care National Audit & Research Centre (ICNARC) model Crit Care Med 2007, 35:1091-1098. 10.1097/ 01.CCM.0000259468.24532.44 17334248
11. Padkin A Goldfrad C Brady AR Young D Black N Rowan K Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland Crit Care Med 2003, 31:2332-2338. 10.1097/01.CCM.0000085141.75513.2B 14501964
12. Bone RC Balk RA Cerra FB Dellinger RP Fein AM Knaus WA Schein RM Sibbald WJ Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644 1303622
13. Vincent JL Bernard GR Beale R Doig C Putensen C Dhainaut JF Artigas A Fumagalli R Macias W Wright T Wong K Sundin DP Turlo MA Janes J Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment Crit Care Med 2005, 33:2266-2277. 10.1097/01.CCM.0000181729.46010.83 16215381
14. Cummings P McKnight B Analysis of matched cohort data Stata J 2004, 4:274-281.
15. Dhainaut JF Laterre PF Janes JM Bernard GR Artigas A Bakker J Riess H Basson BR Charpentier J Utterback BG Vincent JL Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial Intensive Care Med 2003, 29:894-903. 12712239
16. Ely EW Laterre PF Angus DC Helterbrand JD Levy H Dhainaut JF Vincent JL Macias WL Bernard GR Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 2003, 31:12-19. 10.1097/00003246-200301000-00002 12544987
17. Kubler A Mayzner-Zawadzka E Durek G Gaszynski W Karpel E Mikaszewska-Sokolewicz M Majak P Results of severe sepsis treatment program using recombinant human activated protein C in Poland Med Sci Monit 2006, 12:CR107-CR112. 16501420
18. Kanji S Perreault MM Chant C Williamson D Burry L Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study Intensive Care Med 2007, 33:517-523. 10.1007/s00134-007-0555-9 17325837
19. Wheeler A Steingrub J Schmidt GA Sanchez P Jacobi J Linde-Zwirble W Bates B Qualy RL Woodward B Zeckel M A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial Crit Care Med 2008, 36:14-23. 10.1097/ CCM.0b013e318169245a 18158435
20. Vincent JL Laterre PF Decruyenaere J Spapen H Raemaekers J Damas F Rogiers P Sartral M Haentjens T Nelson D Janes J A registry of patients treated with Drotrecogin Alfa (Activated), a new sepsis therapy, in Belgian intensive care units: An observational study Acta Clin Bel 2008, 63:25-30.
21. Angus DC Laterre PF Helterbrand J Ely EW Ball DE Garg R Weissfeld LA Bernard GR The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis Crit Care Med 2004, 32:2199-2206. 10.1097/ 01.CCM.0000114816.62331.08 15640631
22. Bertolini G Rossi C Anghileri A Livigni S Addis A Poole D Use of Drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey Intensive Care Med 2007, 33:426-434. 10.1007/s00134-007-0554-x 17325836
23. Dhainaut JF Payet S Vallet B França LR Annane D Bollaert PE Le Tulzo Y Runge I Malledant Y Guidet B Le Lay K Launois R PREMISS Study Group Cost-effectiveness of activated protein C in real-life clinical practice Crit Care 2007, 11:R99. 10.1186/cc6116 17822547
24. Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL François B Guy JS Brückmann M Rea-Neto A Rossaint R Perrotin D Sablotzki A Arkins N Utterback BG Macias WL Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935 16192478